Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
复制标题
DOI：
10.1016/s0140-6736(04)16725-1
复制
发表时间：
2004-07-24
期刊：
影响因子：
168.9
通讯作者：
Ramsay, ME
中科院分区：
文献类型：
--
作者：
Trotter, CL;Andrews, NJ;Ramsay, ME
英格兰的脑膜炎球菌血清C组合（MCC）疫苗计划成功地控制了血清C疾病的发病率，这是由于疫苗短期的高有效性和大量的群体免疫力。然而，疫苗的长期有效性仍然未知。我们评估了自该规划实施以来4年的监测数据。在补充运动中接种疫苗的儿童（5个月至18岁）的疫苗效力仍然很高。然而，对于在常规婴儿免疫规划中接种疫苗的儿童，MCC疫苗的有效性仅在1年后就降至低水平。这些队列中的个体数量仍然很低，但应考虑替代常规免疫接种计划，以确保维持高水平的保护。
The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.